This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
News|Articles|August 24, 2017
USP Workshops Address Variety of Pharma Issues
Author(s)Pharmaceutical Technology Editors
The US Pharmacopeial Convention is hosting a variety of workshops in Autumn 2017 on a wide range of topics including continuing education, bioassays, and peptides.
Advertisement
The US Pharmacopeial Convention (USP) will be
The following workshops are available:
- Re-thinking Pharmaceutical Technology Continuing Education, Sept. 14–15, 2017. This workshop, cosponsored by the National Institute for Pharmaceutical Technology and Education (NIPTE), will include presentations on NIPTE training programs and USP’s standardization and educational programs. Topics discussed will include pharmaceutical continuing education and education best practices.
- USP’s 7th Bioassay Workshop–Bioassay: A Lifecycle Approach, Sept. 25–26, 2017. This workshop will take a look at how lifecycle and QbD perspectives are being incorporated into bioassays. Lifecycle methods from scientific, statistical, and regulatory perspectives will be discussed.
- Computer Modeling–In-vitro and In-vivo Studies, Oct. 23–25, 2017. This workshop will address how computer modeling and simulation can be useful tools to accelerate product development.
- IPA Probiotic Workshop in DC, Oct. 26, 2017. Cosponsored by the International Probiotics Association, this workshop will foster open dialogue on how probiotics may be considered within regulations.
- 4th USP Workshop on Synthetic Therapeutic Peptides: Regulations, Standards and Quality, Nov. 6–7, 2017. Attendees will learn about USP’s standards and regulatory expectations for peptide products. Strategies for control of raw materials and impurities will be discussed.
Visit
Source:
Advertisement
Related to this article
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Advertisement
Advertisement